Holen Sie sich die Stockscreener-App
28.35
4.27%
1.16
Handel nachbörslich:
28.35
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Volatility Watch: Will Viridian Therapeutics Inc benefit from geopolitical trends2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Patterns Watch: What is the implied volatility of Viridian Therapeutics IncMarket Risk Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn
Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Behavioral Patterns of VRDN and Institutional Flows - Stock Traders Daily
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know - AOL.com
Fund Sells $81M in Viridian Stock: Q4 2025 Portfolio ShiftNews and Statistics - IndexBox
Kynam Capital Management Cuts Viridian Stake by Over $81 Million - Intellectia AI
This fund recently reduced its holding in a Viridian stock by more than $80 million. What does this mean for investors? - Bitget
Is It Too Late To Consider Viridian Therapeutics (VRDN) After Its 82% One-Year Surge? - Yahoo Finance
Is It Time To Reassess Viridian Therapeutics (VRDN) After Its Strong 1-Year Share Price Run? - Sahm
Eyes On Viridian: Major FDA And Trial Milestones On The Horizon - RTTNews
Viridian Therapeutics Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo
Setup Watch: What are the future prospects of Viridian Therapeutics IncWeekly Investment Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Stocks Flashing Renewed Technical Strength: Viridian Therapeutics - MSN
Dow Update: Will Viridian Therapeutics Inc outperform its industry peers2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc. - MarketBeat
How Viridian Therapeutics Inc. stock responds to policy changesMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Earnings Beat: Is Viridian Therapeutics Inc subject to activist investor interestGap Up & Low Risk Investment Opportunities - baoquankhu1.vn
VRDN: Wedbush Reiterates 'Outperform' Rating with $44 Target | V - GuruFocus
Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - MSN
(VRDN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RBC Capital lowers its price target on Viridian Therapeutics, Inc. (VRDN) to $42 and maintains an outperform rating - MSN
Viridian Therapeutics (VRDN) CFO amends Form 4 for tax-share disposal - Stock Titan
Viridian (VRDN) COO adjusts 3,048-share tax withholding in Form 4 amendment - Stock Titan
Viridian Therapeutics (VRDN) legal chief updates tax share disposition - Stock Titan
Viridian Therapeutics (NASDAQ: VRDN) CEO amends Form 4 tax sale - Stock Titan
Analyst Upgrade: Can Viridian Therapeutics Inc be the next market leader2026 Weekly Recap & Consistent Profit Alerts - baoquankhu1.vn
Viridian Therapeutics at Leerink Conference: Eyeing Market Expansion By Investing.com - Investing.com Canada
Published on: 2026-03-07 18:48:40 - baoquankhu1.vn
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Volume Recap: Can Viridian Therapeutics Inc withstand a market correctionJuly 2025 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Can Viridian Therapeutics Inc stock double in the next yearEarnings Beat & Community Trade Idea Sharing Platform - baoquankhu1.vn
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating - Finviz
Vanguard Group Inc. Has $93.48 Million Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - Barchart.com
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Form 4 Viridian Therapeutics Inc For: 5 March By Investing.com - Investing.com Australia
Viridian (VRDN) CEO awarded 559,600 stock options and new RSUs - Stock Titan
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia
[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan
VRDN (NASDAQ: VRDN) Form 144: proposed sale of 1,675 vested shares - Stock Titan
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat
Viridian Therapeutics (VRDN) CMO receives new option and RSU grants - Stock Titan
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews - simplywall.st
Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm
What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru
Truist Financial Sticks to Their Buy Rating for Viridian Therapeutics (VRDN) - The Globe and Mail
How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus
RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):